Related Experiment Video

Updated: Sep 23, 2025

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.0K

Akkermansia muciniphila and its outer membrane protein Amuc_1100 prophylactically attenuate 5-fluorouracil-induced

Shoujun Chen1, Kaiyue Qian1, Guanghui Zhang1

  • 1School of Life Sciences, Anhui University, Hefei, 230601, Anhui, China; Key Laboratory of Human Microenvironment and Precision Medicine of Anhui Higher Education Institutes, Anhui University, Hefei, 230601, Anhui, China.

Biochemical and Biophysical Research Communications
|May 14, 2022
PubMed

Insights

Akkermansia muciniphila and its protein Amuc_1100 protect against chemotherapy-induced intestinal damage. These interventions reduce inflammation, restore gut barrier function, and alter the gut microbiome, offering new therapeutic possibilities.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Pharmacology

Background:

  • 5-Fluorouracil (5-FU) is a widely used chemotherapy agent.
  • 5-FU can cause significant gastrointestinal side effects, including mucositis.
  • Akkermansia muciniphila (A. muciniphila) and its outer membrane protein Amuc_1100 have shown protective effects against colitis.

Purpose of the Study:

  • To investigate the protective effects of A. muciniphila and Amuc_1100 against 5-FU-induced intestinal mucositis in mice.
  • To elucidate the underlying mechanisms of this protection, including inflammatory responses and gut barrier integrity.

Main Methods:

  • Mice were treated with A. muciniphila or Amuc_1100 daily before, during, and after 5-FU injection.
  • Evaluated outcomes included diarrheal toxicity, body weight changes, colonic anatomy, and intestinal histopathology.
  • Quantitative PCR was used to assess cytokine mRNA levels (TNF-α, IL-6), NLRP3 inflammasome activation, and tight junction protein expression.

Main Results:

  • A. muciniphila and Amuc_1100 significantly alleviated 5-FU-induced intestinal mucositis.
  • Both interventions attenuated the upregulation of TNF-α and IL-6, and reduced NLRP3 inflammasome activation.
  • Treatment restored the expression of intestinal tight junction proteins, indicating repair of the gut barrier.
  • A. muciniphila and Amuc_1100 also modulated the structure of the intestinal microbial community.

Conclusions:

  • A. muciniphila and Amuc_1100 demonstrate a protective role against 5-FU-induced intestinal mucositis.
  • These findings suggest potential therapeutic applications of A. muciniphila and Amuc_1100 for managing chemotherapy-related gastrointestinal toxicity.
Keywords:
5-FUA. muciniphilaAmuc_1100Gut microbiotaMucositis

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease06:04

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

Published on: February 9, 2016

21.5K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
726
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
251
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
617
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
630
Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
865
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
571